Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder

IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Emerging Drugs Pub Date : 2024-04-12 DOI:10.1080/14728214.2024.2342951
Sophie Köhne, Thomas Hillemacher, Alexander Glahn, Patrick Bach
{"title":"Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder","authors":"Sophie Köhne, Thomas Hillemacher, Alexander Glahn, Patrick Bach","doi":"10.1080/14728214.2024.2342951","DOIUrl":null,"url":null,"abstract":"Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large....","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"43 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2024.2342951","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large....
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
处于二期和三期临床开发阶段的治疗酒精使用障碍的新药物
酒精使用障碍(AUD)一直给全球健康造成沉重负担。AUD 发病率很高,不仅影响到 AUD 患者,还影响到他们所在的社区和整个社会....。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
0.00%
发文量
28
审稿时长
>12 weeks
期刊介绍: Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.
期刊最新文献
Emerging treatments for sarcoma: from 2024 onward. Emerging biological treatments for asthma. Mitapivat: a step forward across different hemolytic diseases. FcRn inhibitors in the context of myasthenia gravis. Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1